Loading stock data…
OS Therapies Incorporated (OSTX)
$1.83-0.05 (-2.66%)
Market ClosedLast close Sep 8
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OS Therapies Incorporated in the Healthcare sector is trading at $1.83 with a market capitalization of $75M. Wall Street consensus targets $8.50 (4 analysts), implying a +364.5% move over the next 12 months. The stock is currently 22% below its 52-week high of $2.35, remaining 15.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +364.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.17M↑ | -$11.99M↓ | -$6.88M↓ | -$4.84M↑ | -$5.00M |
| Net Income | -$10.40M↑ | -$13.46M↓ | -$6.88M↓ | -$4.54M↓ | -$3.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-H...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$74.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
325.88%
Volume
Today's trading volume
1.75M